Cargando…

Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications

Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanaee-Ahvaz, Hana, Cserjan-Puschmann, Monika, Mayer, Florian, Tauer, Christopher, Albrecht, Bernd, Furtmüller, Paul G., Wiltschi, Birgit, Hahn, Rainer, Striedner, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686840/
https://www.ncbi.nlm.nih.gov/pubmed/38046162
http://dx.doi.org/10.1016/j.heliyon.2023.e22463
_version_ 1785151851422810112
author Hanaee-Ahvaz, Hana
Cserjan-Puschmann, Monika
Mayer, Florian
Tauer, Christopher
Albrecht, Bernd
Furtmüller, Paul G.
Wiltschi, Birgit
Hahn, Rainer
Striedner, Gerald
author_facet Hanaee-Ahvaz, Hana
Cserjan-Puschmann, Monika
Mayer, Florian
Tauer, Christopher
Albrecht, Bernd
Furtmüller, Paul G.
Wiltschi, Birgit
Hahn, Rainer
Striedner, Gerald
author_sort Hanaee-Ahvaz, Hana
collection PubMed
description Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of this study was to answer the question whether functionalization via residue-specific incorporation of the ncAA N(6)-[(2-Azidoethoxy) carbonyl]-l-lysine (Azk) influences the properties of the anti-tumor-necrosis-factor-α-Fab (FTN2). Therefore, FTN2(Azk) variants with different Azk incorporation sites were designed and amber codon suppression was used for production. The functionalized FTN2(Azk) variants were efficiently produced in fed-batch like μ-bioreactor cultivations in the periplasm of E. coli displaying correct structure and antigen binding affinities comparable to those of wild-type FTN2. Our FTN2(Azk) variants with reactive handles for diverse conjugates enable tracking of recombinant protein in the production cell, pharmacological studies and translation into new pharmaceutical applications.
format Online
Article
Text
id pubmed-10686840
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106868402023-12-01 Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications Hanaee-Ahvaz, Hana Cserjan-Puschmann, Monika Mayer, Florian Tauer, Christopher Albrecht, Bernd Furtmüller, Paul G. Wiltschi, Birgit Hahn, Rainer Striedner, Gerald Heliyon Research Article Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of this study was to answer the question whether functionalization via residue-specific incorporation of the ncAA N(6)-[(2-Azidoethoxy) carbonyl]-l-lysine (Azk) influences the properties of the anti-tumor-necrosis-factor-α-Fab (FTN2). Therefore, FTN2(Azk) variants with different Azk incorporation sites were designed and amber codon suppression was used for production. The functionalized FTN2(Azk) variants were efficiently produced in fed-batch like μ-bioreactor cultivations in the periplasm of E. coli displaying correct structure and antigen binding affinities comparable to those of wild-type FTN2. Our FTN2(Azk) variants with reactive handles for diverse conjugates enable tracking of recombinant protein in the production cell, pharmacological studies and translation into new pharmaceutical applications. Elsevier 2023-11-20 /pmc/articles/PMC10686840/ /pubmed/38046162 http://dx.doi.org/10.1016/j.heliyon.2023.e22463 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Hanaee-Ahvaz, Hana
Cserjan-Puschmann, Monika
Mayer, Florian
Tauer, Christopher
Albrecht, Bernd
Furtmüller, Paul G.
Wiltschi, Birgit
Hahn, Rainer
Striedner, Gerald
Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications
title Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications
title_full Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications
title_fullStr Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications
title_full_unstemmed Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications
title_short Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications
title_sort antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - a door opener for new biological and therapeutic applications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686840/
https://www.ncbi.nlm.nih.gov/pubmed/38046162
http://dx.doi.org/10.1016/j.heliyon.2023.e22463
work_keys_str_mv AT hanaeeahvazhana antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT cserjanpuschmannmonika antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT mayerflorian antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT tauerchristopher antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT albrechtbernd antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT furtmullerpaulg antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT wiltschibirgit antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT hahnrainer antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications
AT striednergerald antibodyfragmentsfunctionalizedwithnoncanonicalaminoacidspreservingstructureandfunctionalityadooropenerfornewbiologicalandtherapeuticapplications